AtriCure (NASDAQ:ATRC) Director Sells $288,070.86 in Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Regina Groves sold 5,313 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the sale, the director owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

AtriCure Price Performance

NASDAQ ATRC opened at $57.14 on Thursday. The business’s fifty day moving average is $43.82 and its 200 day moving average is $34.09. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $57.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market capitalization of $2.91 billion, a PE ratio of 272.11 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Harbor Investment Advisory LLC bought a new stake in AtriCure in the second quarter worth $40,000. Allworth Financial LP bought a new position in AtriCure during the second quarter valued at $43,000. Integrated Wealth Concepts LLC bought a new position in AtriCure during the second quarter valued at $46,000. Fifth Third Bancorp purchased a new position in shares of AtriCure in the 1st quarter worth $51,000. Finally, Global Retirement Partners LLC bought a new stake in shares of AtriCure in the 2nd quarter worth about $52,000. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ATRC. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. UBS Group dropped their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Piper Sandler lifted their target price on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Finally, Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, AtriCure presently has an average rating of “Moderate Buy” and an average price target of $52.00.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.